Andrew Bellinger - 13 Jul 2022 Form 4 Insider Report for Verve Therapeutics, Inc. (VERV)

Role: CSO & CMO
Signature: /s/ Andrew Ashe, as Attorney-in-Fact for Andrew Bellinger
Issuer symbol: VERV
Transactions as of: 13 Jul 2022
Net transactions value: -$234,200
Form type: 4
Filing time: 15 Jul 2022, 17:00:23 UTC
Previous filing: 15 Feb 2022
Next filing: 22 Jul 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	VERV	Common Stock	Options Exercise	$14,800	+10,000	+151%	$1.48^*	16,629	13 Jul 2022	Direct	F1
transaction	VERV	Common Stock	Sale	$249,000	-10,000	-60%	$24.90	6,629	13 Jul 2022	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	VERV	Stock Option (right to buy)	Options Exercise	$0	-10,000	-6.8%	$0.000000	136,995	13 Jul 2022	Common Stock	10,000	$1.48	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Includes 1,629 shares of the Company's common stock acquired under the Verve Therapeutics, Inc. Amended and Restated 2021 Employee Stock Purchase Plan.
F2	The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 20, 2022.
F3	The remaining shares underlying this option, which was granted on September 17, 2019 and commenced vesting on October 1, 2019, vest in equal monthly installments until October 1, 2023.